Cargando…
A Population Pharmacokinetic and Pharmacodynamic Analysis of RP5063 Phase 2 Study Data in Patients with Schizophrenia or Schizoaffective Disorder
BACKGROUND AND OBJECTIVE: RP5063 is a novel multimodal dopamine (D)–serotonin (5-HT) stabilizer possessing partial agonist activity for D(2/3/4) and 5-HT(1A/2A), antagonist activity for 5-HT(2B/2C/7,) and moderate affinity for the serotonin transporter. Phase 2 trial data analysis of RP5063 involvin...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6133081/ https://www.ncbi.nlm.nih.gov/pubmed/29619682 http://dx.doi.org/10.1007/s13318-018-0472-z |